
Auris Medical has revealed promising new in vitro data for AM-301, its drug-free nasal spray, showing that the product could …

Auris Medical (NASDAQ: EARS) has announced that it has initiated enrolment for a new Phase III trial that will evaluate …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

